Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.
Hagell P, Höglund A, Hellqvist C, Johansson EL, Löwed B, Sjöström AC, Karlberg C, Lundgren M, Dizdar N, Johansson A, Willows T, Rådberg J, Bergquist F.
Hagell P, et al. Among authors: johansson a, johansson el.
J Neurol. 2020 Nov;267(11):3411-3417. doi: 10.1007/s00415-020-10031-1. Epub 2020 Jul 1.
J Neurol. 2020.
PMID: 32613445
Free PMC article.